為了更好的用戶體驗，請使用 Chrome 或者 Safari 瀏覽器進行訪問。
Please change your browser to Chrome or Safari for a better experience.
“Carcinoma-in-situ” or “CIS” shall mean a histologically proven, localised pre-invasion lesion where cancer cells have not yet penetrated the basement membrane or invaded (in the sense of infiltrating and/or actively destroying) the surrounding tissues or stroma in any one of the following covered organ groups, and subject to any classification stated:
(a) breast, where the tumour is classified as Tis according to the TNM Staging method;
(b) uterus, vagina, vulva or fallopian tubes where the tumour is classified as Tis according to the TNM Staging method or FIGO Stage 0;
(c) cervix uteri, classified as cervical intraepithelial neoplasia grade III (CIN III) or as Tis according to the TNM Staging method or FIGO* Stage 0;
(d) ovary – include borderline ovarian tumours with intact capsule, no tumour on the ovarian surface, classified as T1aN0M0 (TNM Staging) or FIGO 1A;
(e) Colon and rectum;
(j) Stomach and esophagus;
(k) Urinary Bladder – Tis or Ta according to the TNM Staging method; or
For purposes of this Policy, Carcinoma-in-situ must be confirmed by a biopsy.
Is this question and answer helpful to answer your question?